Clinical Trial Search

Primary: Chronic Effectiveness (Through 6 Months) of the Freezor Xtra Catheter for the Treatment of AVNRT Using an Endocardial Approach. — 368; 29 Participants — p=<0.0001

Primary: The Maximum Reduction in Ventricular Rate, Measured on Holter Monitoring, Within 60 Minutes From Drug Administration. — 135.5; 130.3; 130.7; 95.2 bpm — p=<0.0001

Primary: Comparison of the Percentage of Patients With Scar in Each Segment as Determined by MIBG SPECT Versus Electroanatomic at Baseline — 2; 4; 1; 4 Participants

Primary: Number of Participants With Recurrence of Ventricular Tachycardia — 13; 13 Participants

Primary: Number of Serious Adverse Events — 2; 0; 0; 1 Events

Primary: Number of Participants With Adverse Events for Self-administered Etripamil NS Outside of the Clinical Setting. — 324 Participants

Primary: Number of Patients With Reduction ≥ 15% in Left Ventricular End-systolic Volume (LVESV) — 5; 6 Participants — p=1.00

Primary: Number of Subjects Without Hospitalization for Ventricular Tachycardia (VT) During 6 Months — 38 Participants

Primary: The Percentage of Chronic Success of the NAVISTAR THERMOCOOL Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (PAF) — 66; 16 Percentage of…

Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants

Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants

Primary: A Composite of the Total Number of Participants With Either Tachycardia Change or Tachycardia Termination With First Ablation Set. — 38; 29 Participants

Primary: Atrial Tachyarrhythmia Recurrence in Participants — 37 participants

Primary: The Percentage of Subjects That Expire From All-cause Mortality Within 12-months Post Ablation. — 13.3 percentage of mortality

Primary: Percentage of Participants Free From VT at 1 Year Post-Treatment — 62 percentage of participants free from VT

Primary: Slow Ventricular Tachycardia Episodes Devices Detected (Between 120-150 Bpm and > 30sec) Atrial Fibrillation (AF) Episodes Devices Detected (> 30 Sec) — 3778; 112; 68…

Primary: All Hospital Episodes (Emergency Room or Patient Request for OPD) Related to Treatment for Atrial Arrhythmia — 19; 76; 23 Participants — p=<0.0001

Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001

Primary: Number of Participants Who Had Freedom From Ventricular Arrhythmia at 6 Months — 8; 4; 5; 2 Participants

Primary: Number of Participants With Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events — 71; 14; 85; 83 Participants

Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV

Primary: Number of Electrocardiograms (ECGs) Collected — 77; 67; 53 ECG

Primary: Unplanned Hospital Admissions for Cardiac Reasons OR Death of Cardiovascular Causes OR Progression to Chronic Atrial Fibrillation — 43; 44 participants

Primary: Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months. — 74 percentage of subjects

Primary: Atrial Fibrillation Burden — 2; 8.5 Percent time spent in atrial fibrillatio

Primary: Inhibition of Idiopathic Ventricular Tachycardia

Primary: Electrogram Duration at Digital Twin Predicted Sites Compared to Non-predicted Sites — 77.5; 65.7 ms

Primary: Freedom From Recurrent VT, Cardiovascular Rehospitalization, and All-cause Mortality — 33; 25; 28; 27 Participants

Primary: Dose-response Relationship for QTcF Interval of AZD1305 — 461; 486; 490; 482 ms

Primary: The Incidence of Early Onset Primary Adverse Events — 5.5 percentage of participants